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In describing what is new in the management of 
malignant brain tumors, I shall confine myself largely 
to chemotherapy and shall outline what we think is 
important based on our own experience, what we 
have achieved with single and multiple agents, and 
where we are going. We have just reviewed our five-
year experience and find that chemotherapy, perhaps, 
is the only thing that is new. 
The development of drugs since 1943 has been 
escalating at a fantastic rate. Today, we can provide 
the chemotherapist with a wide array of drugs from 
which to choose. 
Several neoplastic diseases are now recognized 
as being highly responsive to chemotherapy and the 
list is growing. The first to be recognized was 
childhood lymphocytic leukemia, then choriocar-
cinoma, and now testicular carcinoma and Wilm's 
tumor. 
The first consideration for effective brain tumor 
chemotherapy, as we see it, is that the agent must 
have optimum lipid solubility or a special transport 
system. We are convinced that it must penetrate the 
normal brain to be truly effective, and I shall indicate 
our reasoning below. 
One must achieve an adequate drug level in 
brain adjacent to the tumor with minimal or no 
neural toxicity, and the drug must be given frequently 
enough to produce maximal DNA damage with in-
sufficient time for repair. At the present time, we are 
studying the rate of DNA damage and repair in a 
search for combinations of drugs that will give less 
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than added tox1c1ty and, at the same time, will 
produce synergistic antitumor effects. 
A water soluble compound is excluded by the in-
tact blood-brain barrier and, administered in-
travenously, the drug attains a high concentration 
only in the leaky, central portion of the tumor. As the 
drug moves toward ventricular and subarachnoid 
cerebral spinal fluid (CSF), the concentration falls 
very rapidly, so that the active periphery of the tumor 
is exposed to low concentrations of its drug and for a 
brief time orily. If one gives a water-soluble drug in 
the CSF, however, it moves quickly across the epen-
dyma into adjacent brain. It does not exit from the 
normal brain but diffuses through brain into tumor. 
This would be a reasonable way, then, to give a 
water-soluble drug. 
On the other hand, if one uses a lipid-soluble 
agent, for example, the nitrosoureas, it crosses 
capillaries in the normal brain. Obviously, it crosses 
the tumor's leaky capillaries, so that one has equal 
drug concentrations in brain adjacent to tumor and 
in tumor. If one injects a lipid-soluble drug into the 
ventricle, it crosses the ependyma, instantly goes out 
through the capillaries of the normal brain, and none 
of it ever reaches the tumor, unless it happens to be 
very close. It would be irrational to use a lipid-soluble 
drug intrathecally. With lipid-soluble compounds, 
concentration in the tumor is the same as concentra-
tion in the brain. We believe that this is important 
both from the theoretical standpoint and from our 
own experience. 
Our group is interested in developing effective 
drugs and drug schedules in the laboratory and in 
bringing these into clinical trials. We started out with 
a rat glioma; now we have two rat gliomas and three 
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mouse gliomas, which we use for drug screening. In 
the past, we have used reservoirs in pups for in-
trathecal administration. We can perform intrathecal 
injections in the rat, so that it provides a model for 
therapy, either by continuous intra-arterial infusion 
or by intrathecal injection. We are not limited by the 
route of administration. It turns out that the models 
have been extremely useful, not. only for screening 
promising compounds but also for working out drug 
schedules and routes for administration. 
The kinetics of brain tumors are most important. 
We have studied animal tumors and have completed 
studies of human tumors in vivo. To summarize what 
we know about a glioblastoma at the present time, we 
have shown that in a glioblastoma, approximately 
30% of viable cells are actively dividing and the other 
70% of the cells are nondividing (nonproliferating). 
The cell cycle, that is, the length of time it takes a 
glioblastoma cell to go from one mitosis to two cells 
at the next mitosis, is somewhere in the range of 21 2-3 
days. Were it not for a very high rate of cell loss, the 
volume of a glioblastoma would double in ap-
proximately one week. This is unrealistic on the basis 
of clinical observation. We know that the period of 
time required for the glioblastoma cell to synthesize 
its DNA is about 9-10 hours and, interestingly 
enough, it takes an astrocytoma the same period of 
time. 
In our studies, we have used radioactive 
thymidine, labelled either with tritium or with 14C. 
We have documented the intense proliferation seen in 
blood vessels within a glioblastoma. In all probabili-
ty, the limiting factor in the growth rate of a 
glioblastoma is the rate at which the blood vessels can 
proliferate, because there is good reason to believe 
that the capillary endothelium cannot divide as rap-
idly as tumor cells. In brain adjacent tumor, in 
the absence of tumor cells, because of tumor 
angiogenesis factor, blood vessels proliferate in ad-
vance of invasive tumor. 
The brain presents a particular problem. After 
treatment with an effective chemotherapeutic agent, a 
dead cell takes up approximately twice as much room 
as living cell. The result is an increment of edema or 
swelling of tumor cells and an increase in volume. 
This increased volume can be detrimental because of 
the effects of an increase in intracranial pressure. 
Dead cells must be removed; although these cells are 
now nonviable, they are still present and therefore act 
as a mass. We have just completed studies on dead-
cell removal and have shown that when one puts 
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tagged, lethally irradiated cells in brain, muscle, and 
subcutaneously, brain has a most inefficient, sluggish 
means of dead-cell disposal. We are convinced, both 
from pathological studies as well as our own obser-
vations, that the brain is relatively inefficient in 
removing dead cells as opposed to other solid organs. 
At this period, we often have to use steroids to com-
bat increased intracranial pressure and the question 
arises as to what steroids do to tumors? 
Methyl prednisolone or any of the glucocor-
ticoids will increase the survival of tumor-bearing 
animals that receive the steroids. Thus, you can in-
crease the survival of a rat bearing a glioma by giv-
ing steroids. If one has a control group and a group 
treated with methyl prednisolone, and they are killed 
at the same time (in this instance on the 21st day) one 
finds that the tumors in the control animals vary 
pretty widely but •have a mean weight of 157 mg, 
whereas the tumors of the animals receiving steroids 
are much smaller with a mean weight of 36 mg. One 
can explain this difference in two ways-steroids kill 
tumor cells and steroids slow down the rate of cell 
proliferation. We now have evidence that the latter is 
true. There is no direct oncolytic effect on glial 
tumors, but the steroid simply puts certain 
proliferating cells into a nonproliferating state, and it 
also increases the period of time necessary for a cell 
to divide, that is, the cell cycle time. This became very 
important when we checked our own clinical 
statistics. Were we confusing ourselves in judging 
drugs by the concomitant use of steroids? To answer 
the question, we took consecutive patients. One 
group of patients never received steroids. With an ap-
proximately equal number of patients in both groups, 
we determined how many were chemotherapy 
responders, probable responders and nonresponders. 
The concomitant use of steroids did not change the 
frequency of response to chemotherapy. We have 
concluded that steroids have one major effect in the 
brain tumor patient, that of reducing cerebral edema. 
To date, we have no clinical evidence that they have 
any effect on tumor cells. 
The material that I intend to present is based on 
a particular group of patients. These are patients who 
either have tumors recurrent following surgery and 
radiation therapy or in whom the diagnosis of a 
malignant tumor could be made without any 
reasonable doubt and whom we elect to treat by 
chemotherapy rather than by radiation therapy. In 
the latter group, we do not insist upon a tissue 
diagnosis, feeling that the price of obtaining a tissue 
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diagnosis is to justify the biopsy of a glioblastoma or 
a brain stem glioma . For reasons that I shall point 
out, this is more often the case. 
Consequently, patients who are eligible for our 
Phase II trials are those either with recurrent tumors 
or with primary tumors who are considered can-
didates for primary chemotherapy without surgical 
verification. In addition, we treat a small number of 
patients with metastatic tumors. A phase II trial asks 
one question: Is the drug effective, that is, does this 
drug have some activity against the tumor? It asks 
neither what the cure rate is nor for how long . A 
phase II study is designed solely for searching out and 
identifying effective drugs. For a patient to be eligible 
for this kind of study, he must first be ineligible for 
other studies in our program. Second, with a 
pathological diagnosis or an unequivocal ra-
diographic and clinical picture, . the patient is de-
teriorating neurologically. Third, if radiotherapy 
has been given, it must have been completed at least 
three months prior to chemotherapy. Dead cells hang 
around after the completion of radiotherapy, and late 
improvement can occur following radiotherapy. As a 
matter of fact, since we have instituted this rule, we 
have actually confirmed delayed improvement up to 
three months after radiotherapy. Finally, the patient 
is expected to live at least two months, and we are 
sometimes wrong on that estimate, but the patient, or 
more often his family, understands the complications 
of chemotherapy. Parenthetically, I can say that we 
have lost approximately 1 % of our patients as a direct 
result of complications of chemotherapy; our mor-
bidity has been higher. Mortality has remained low 
because we have means of rescuing the patient who 
gets thrombocytopenia or leukopenia. 
Thirty-four patients were not treated because: 1) 
we found no evidence of tumor regrowth, 2) we 
thought that they would live less than two months, 3) 
they declined treatment after understanding it, or 4) 
further surgery was elected. In the latter category, a 
benign fourth ventricle cyst was referred to us as a 
recurrent brain stem glioma, and we sent the patient 
back with diagnostic studies to the referring 
neurosurgeon who removed the cyst. Recently, I 
removed a nerve sheath tumor of the tenth nerve 
which had been misdiagnosed as a brain stem glioma 
and, after radiation therapy, was sent to us for 
chemotherapy. We have seen a ·variety of misdiag-
nosed lesions, emphasizing the need for careful study. 
In one patient, we thought radiotherapy was the 
treatment of choice. 
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To judge the effect of chemotherapy, we use two 
criteria. We have a third which will probably be 
added-the EEG (which came as a complete surprise 
to me). At first, I would not allow our elec-
troencephalographer to charge our patients, because I 
was convinced that EEG would be valueless, but it 
did just about as well as a scan in predicting whether 
a patient was better or worse. We, like others, will be 
looking to the EMI scanner for a fourth criterion . 
The two criteria on which our data are based are the 
clinical status and the brain scan . A patient classed as 
a responder is better clinically and his brain scan is 
better. A patient is designated a probable responder if 
clinical status is: 1) improved and the brain scan is the 
same, 2) if the clinical status is the same and the brain 
scan is better, or 3) if both of them remain the same 
for at least three months in the case of me-
dulloblastomas and glioblastomas and six months 
for more benign tumors. A nonresponder de-
teriorates as judged by clinical status and brain scan. 
A certain number of patients in our series were 
nonevaluable. We determined, in retrospect, that 
patients surviving for less than two months after 
beginning treatment were not evaluable-again, 
because of the slow removal of dead cells. Ap-
proximately 15% of all responders were considered 
failures when they returned for their second course of 
therapy. If a patient receiving a course of 
chemotherapy is obviously worse six weeks later, it 
does not mean that the drug is ineffective, because 
among those patients who eventually turn out to be 
unequivocable responders, 15% have had an initial 
deterioration in brain scan and clinical condition . 
Several patients were nonevaluable because, in the 
beginning, we were inexperienced . In some, the 
neurological condition was not clearly deteriorating 
immediately prior to treatment; others failed to com-
plete one full course; and on five patients, we were 
unable to obtain an adequate follow-up. 
What can we expect in using single drugs? With 
BCNU (still the best single drug used to date), 27 of 
our 57 patients showed a response, a rate of 47% over 
a mean duration of nine months, and this a popula-
tion of recurrent tumors . CCNU has a response rate 
of 44% but for a shorter mean duration. Procar-
bazine, also a powerful drug with a 52% response 
rate, has a mean duration of six months. We are un-
able to give an explanation for the fact that when we 
combine BCNU and vincristine (which should be a 
good combination because vincristine is not toxic to 
the bone marrow), we get a response rate of only 45% 
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over four months. Although BCNU and CCNU are 
virtually identical and both are highly lipid soluble, 
BCNU seems to have a clear advantage. Procarbazine 
is not lipid soluble, but it does proceed rapidly, in 
high concentration, into CXF. The three most effec-
tive single agents, thus, have in common bone 
marrow toxicity and very rapid entry into brain and 
into CSF. 
What of the patient who receives a first drug 
and, whether with or without response, then proceeds 
with a second drug? A response to a second drug is 
very small, probably for two reasons-one, a possible 
cross resistance and two, by the time of proceeding to 
a second drug, the patient is usually in poor 
condition. 
What can be said of tumor types as related to 
specific drugs? With malignant gliomas and 
astrocytomas or glioblastomas, the response is 
similar with all of the three most effective drugs. For 
ependymomas, BCNU is extremely good, one of our 
patients responding to BCNU as the second drug ad-
ministered. The other tumor-specific chemotherapy, 
which I shall go into later, is the combination of 
procarbazine, CCNU, and vincristine that seems to 
be highly effective for medulloblastomas. 
As must be well known, BCNU is given in-
travenously on various schedules; it is quite likely 
that we do not use the optimal schedule. One of our 
early patients, a quadriplegic with an ependymoma, 
had a fantastic response over several months to 
BCNU, but ultimately could not receive any more 
due to the development of cumulative bone marrow 
toxicity. One patient with a malignant astrocytoma, 
having been treated with BCNU for two years, shows 
no evidence of tumor regrowth after two and one-half 
years off treatment. One young boy, who had a 
recurrent ependymoma of the fourth ventricle with 
supratentorial metastases, tumor cells in his CSF, 
and recurrent tumor in his posterior fossa, was 
treated with BCNU for two and one-half years; he is 
attending college now with no evidence of recurrent 
disease after two years off treatment. 
The Brain Tumor Study Group has studied 
BCNU in a phase III trial, taking patients who had 
had a major craniotomy and removal of a supraten-
torial glioblastoma. Postoperatively, these patients 
were not dependent upon steroids and they ran-
domized within three weeks of operation; thus, this is 
a select group of patients treated in the early 
postoperative period. Patients who received no 
further treatment had a median survival of 15 
203 
weeks-a little less than four months, which seems to 
be a little on the low side. Those patients who re-
ceived only BCNU postoperatively had a median sur-
vival of 21 weeks; those who received irradiation 
therapy had a median survival of 30 weeks; and those 
receiving BCNU plus irradiation had a median sur-
vival of 40 weeks. How do we interpret this? Irradia-
tion and BCNU combined are better than either 
alone and better than no further treatment after sur-
gery as well. Of the various forms of adjuvant therapy 
reported for glioblastomas, the most effective is 
BCNU and irradiation combined following major 
tumor removal. At the time of this study, about four 
years ago, BCNU was used because it had been 
shown to be an active drug in phase II trials. 
One of the people in our laboratory became an 
expert at removing rat gliomas, and we evaluated ad-
juvant chemotherapy and surgery, using a rat brain 
tumor model. We asked: Are we giving BCNU at the 
right time? Should it be given before operation, with 
the operation, or afterwards? We tried various com-
binations of BCNU and surgery and in one group, we 
even added 5-FU to obtain early proliferating 
postoperative cells. The study showed that there was 
no combination of surgery and BCNU that was as 
beneficial as BCNU alone. I could not believe it and 
we repeated the experiments four times. The ex-
periments defied my prejudice and the basic laws of 
cell kinetics, and the results have now been submitted 
for publication. I do not believe, however, that on 
this basis, neurosurgeons will stop removing 
glioblastomas, but we did feel encouraged to treat a 
few human glioblastomas, diagnosed angiographi-
cally without histological verification. Of the pa-
tients treated in this way, only two harbored pri-
mary reticulum cell sarcomas that we called 
glioblastomas-not a large error. 
Procarbazine is a monoamine oxidase inhibitor 
and patients under treatment, therefore, cannot eat 
ripe cheese or take certain drugs. One patient, who 
showed excellent results by brain scan, became 
irreversibly psychotic, so it is not a perfect drug, but 
it does move rapidly into the CSF. In one of our first 
patients, with a recurrent medulloblastoma and a 
total spinal block, procarbazine alone melted away 
the mass. Though active against medulloblastomas, 
procarbazine alone is not as active as a more recent 
drug combination to be mentioned below. Its activity 
against malignant gliomas is similar to BCNU. 
Single drug therapy for solid tumors is rarely 
curative in animal or human systems after the tumor 
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reaches a clinical size. Those people interested in 
solid tumors, therefore, are looking to combination 
chemotherapy, using drugs that have qualitatively 
different toxicity and complimentary mechanisms of 
action to prevent the emergence of resistance clones, 
and are combining agents that act on cycling versus 
noncycling (nonproliferating) cells. 
Our first multiple drug protocol involved three 
drugs : CCNU, which we knew was active and could 
be given by mouth; vincristine, which was active and 
did not add toxicity to the bone marrow; and procar-
bazine, which we thought was an excellent drug. The 
course was given on a 28-day cycle: CCNU on day I, 
procarbazine for the first 14 days, and vincristine 
twice (days I and 8). We obtained a response rate of 
57% (I cannot give the median duration, but it has 
produced some of the most dramatic responses we 
have seen with medulloblastomas.). We are now per-
suaded for the first time, that we have something safe 
enough and effective enough to justify designing a 
study of combining chemotherapy with radiotherapy 
for the immediate treatment of verified me-
dulloblastomas. Our response rate here has been 
well over 75%, but the patients do develop chronic 
bone marrow toxicity. For example, a little girl who 
came in with papilledema and huge subfrontal 
metastases had a normal brain scan two months ago, 
after receiving procarbazine, CCNU, and vincristine, 
but due to chronically depressed bone marrow, we 
are unable to give her more drug and she is expe-
riencing a recurrence. 
We tried the combination of Cytoxan® 
(cyclophosphamide), CCNU, and vincristine. We 
saw few responses and concluded that this is not an 
effective combination. 
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What are the approaches to more effective 
chemotherapy? We are convinced that drug com-
binations are the wave of the future. Simultaneously, 
we are trying to identify new effective single drugs 
and effective combinations of single drugs. We are 
now actually putting into practice schedules based on 
kinetic information, that is, cell cycle and number or 
percentage of proliferating cells. It may be possible to 
convert tumor cells that are nonproliferating into a 
proliferating state in which they are more susceptible 
to drugs specifically damaging to proliferating cells. 
Possibly, we can convert some normal cells, such 
as gut and bone marrow, from their normal 
proliferating state to a noncycling compartment, par-
ticularly bone marrow, so that it will not be 
devastated by the drugs we use. We do not have a 
single drug today that is specific for cancer cells and 
are always on a tight wire between poisoning the host 
and poisoning the cancer. 
We hear a great deal about enhancing immune 
mechanisms. In the one reported study, patients who 
were immunized did no better than those who were 
not. There are some very promising things on the 
horizon, but at the moment, I see no immediate role 
for immunotherapy. The successful acceleration of 
dead cell disposal, in which we are extremely in-
terested, will have some practical application. 
In summary, our studies have identified three 
agents individually active against a variety of brain 
tumors. Procarbazine belongs in another phar-
macological group, but BCNU and CCNU are 
similar. Combination chemotherapy holds great 
promise for brain tumor chemotherapy, and one of 
the two combinations evaluated by us is highly effec-
tive against medulloblastomas. 
